Methotrexate in psoriasis and psoriatic arthritis by Coates, L, Merola, J, Grieb, SM, Mease, PJ, Duffin, KC

“…Methotrexate (MTX) is the most commonly prescribed first-line therapy in psoriatic arthritis (PsA) internationally and is also commonly used in the treatment of psoriasis. However, data supporting its use in PsA are limited and significant toxicities can occur. …”

Identification of psoriatic arthritis in patients with psoriasis by Coates, LC, Eder, L, Poddubnyy, D, Rosen, CF

“…People with psoriasis are at increased risk of developing psoriatic arthritis. …”

Is traditional Chinese medicine effective for the management of psoriasis? by Onakpoya, I

Validation of a new measure of patient global assessment in psoriasis by Gollins, CE, Coates, LC

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 by Smith, CH, Jabbar-Lopez, ZK, Yiu, ZZ, Bale, T, Burden, AD, Coates, LC, Cruickshank, M, Hadoke, T, MacMahon, E, Murphy, R, Nelson-Piercy, C, Owen, CM, Parslew, R, Peleva, E, Pottinger, E, Samarasekera, EJ, Stoddart, J, Strudwicke, C, Venning, VA, Warren, RB, Exton, LS, Mustapa, MF

“…The overall aim of the guideline is to provide evidence-based recommendations on the use of biologic therapies (adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab) in adults, children and young people for the treatment of psoriasis; consideration is given to the specific needs of people with psoriasis and psoriatic arthritis. …”

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same? by Coates, L, Fitzgerald, O, Helliwell, P, Paul, C

“…Articles were reviewed and summarized according to disease area (psoriasis, psoriatic arthritis, and rheumatoid arthritis).…”

The role of epigenetics and immunological imbalance in the etiopathogenesis of psoriasis and psoriatic arthritis by Frischknecht, L, Vecellio, M, Selmi, C

“…Psoriasis (Ps) and psoriatic arthritis (PsA) represent a clinical and immunopathogenic continuum, called psoriatic disease, cumulatively affecting approximately 3% of the general population. …”

Transglutaminase 3 reduces the severity of psoriasis in imiquimod-treated mouse skin by Piro, MC, Ventura, A, Smirnov, A, Saggini, A, Lena, AM, Mauriello, A, Bianchi, L, Melino, G, Candi, E

“…In this paper, we focused on the roles of TG2 and TG3 in imiquimod-induced psoriasis in mouse skin. We evaluated the severity of psoriasis markers in the skin of imiquimod-treated TG3 null and TG2 null mice. …”

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. by Palfreeman, A, McNamee, K, McCann, F

“…Psoriasis is a chronic inflammatory skin disease, most commonly resulting in the occurrence of red and silver scaly plaques. …”

Assessment of two screening tools to identify psoriatic arthritis in patients with psoriasis by Coates, L, Savage, L, Chinoy, H, Laws, P, Lovell, C, Korendowych, E, Mahmood, F, Mathieson, H, McGonagle, D, Warren, R, Waxman, R, Helliwell, P

“…<br/><strong>Background: </strong>Many patients with psoriasis have undiagnosed psoriatic arthritis. Low specificity is found with many PsA screening tools. …”

Is axial psoriatic arthritis the same as ankylosing spondylitis with psoriasis: a debate by Coates, LC, Deodhar, A

“…During the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2022 conference, Drs. …”

Evidence that a locus for familial psoriasis maps to chromosome 4q. by Matthews, D, Fry, L, Powles, A, Weber, J, McCarthy, M, Fisher, E, Davies, K, Williamson, R

“…Psoriasis is an inflammatory skin disease that affects 2% of the population. …”

HLA-C LOCUS GENOTYPING IN PSORIASIS USING SEQUENCE-SPECIFIC AMPLIFICATION PRIMERS by Mallon, E, Bunce, M, Welsh, K, Wojnarowska, F

Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis by Mahil, SK, Ezejimofor, MC, Exton, LS, Manounah, L, Burden, AD, Coates, LC, de Brito, M, McGuire, A, Murphy, R, Owen, CM, Parslew, R, Woolf, RT, Yiu, ZZN, Uthman, OA, Mohd Mustapa, MF, Smith, CH

“…<p><strong>Background</strong> The rapid expansion of psoriasis biologics has led to an urgent need to understand their relative efficacy and tolerability to inform treatment decisions better and, specifically, to inform guideline development.…”

Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. by Tsoi, L, Spain, S, Knight, J, Ellinghaus, E, Stuart, P, Capon, F, Ding, J, Li, Y, Tejasvi, T, Gudjonsson, J, Kang, H, Allen, M, McManus, R, Novelli, G, Samuelsson, L, Schalkwijk, J, Ståhle, M, Burden, A, Smith, C, Cork, M, Estivill, X, Bowcock, A, Krueger, G, Weger, W, Worthington, J

“…To gain further insight into the genetic architecture of psoriasis, we conducted a meta-analysis of 3 genome-wide association studies (GWAS) and 2 independent data sets genotyped on the Immunochip, including 10,588 cases and 22,806 controls. …”

A cross-sectional survey of the nature and correlates of sleep disturbance in people with psoriasis by Henry, A, Kyle, S, Chisholm, A, Griffiths, C, Bundy, C

“…BACKGROUND: Research suggests that sleep disturbance is common in psoriasis. While several sleep investigations have been conducted in psoriasis populations, many have methodological shortcomings, and no study has examined multiple dimensions of sleep-wake functioning. …”

Disease severity in Ankylosing Spondylitis: The influence of associated inflammatory bowel disease and psoriasis by Bradbury, L, Lewington, M, Warner, J, Farrar, C, Wordsworth, B, Brown, M

Psoriasis patients are enriched for genetic variants that protect against HIV-1 disease. by Chen, H, Hayashi, G, Lai, O, Dilthey, A, Kuebler, P, Wong, T, Martin, M, Vina, F, McVean, G, Wabl, M, Leslie, K, Maurer, T, Martin, J, Deeks, S, Carrington, M, Bowcock, A, Nixon, D, Liao, W

“…We analyzed the HLA class I and class II alleles of 1,727 Caucasian psoriasis cases and 3,581 controls and found that psoriasis patients are significantly more likely than controls to have gene variants that are protective against HIV-1 disease. …”

A framework for multi-omic prediction of treatment response to biologic therapy for psoriasis. by Foulkes, AC, Watson, DS, Carr, DF, Kenny, JG, Slidel, T, Parslew, R, Pirmohamed, M, PSORT Consortium, Anders, S, Reynolds, NJ, Griffiths, CEM, Warren, RB, Barnes, MR

“…Biologic therapies have shown high efficacy in psoriasis, but individual response varies and is poorly understood. …”

Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity by Tsoi, L, Tsoi, L, Spain, S, Spain, S, Knight, J, Knight, J, Knight, J, Ellinghaus, E, Ellinghaus, E, Stuart, P, Capon, F, Ding, J, Li, Y, Tejasvi, T, Gudjonsson, J, Kang, H, Allen, M, McManus, R, McManus, R, Novelli, G, Novelli, G, Samuelsson, L, Schalkwijk, J, Ståhle, M, Burden, A

“…To gain further insight into the genetic architecture of psoriasis, we conducted a meta-analysis of 3 genome-wide association studies (GWAS) and 2 independent data sets genotyped on the Immunochip, including 10,588 cases and 22,806 controls. …”